Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Solitary Fibrous Tumors 1Sarcoma 1Polycystic Ovary Syndrome 1Neoplasm Metastasis 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Lung Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Granuloma, Plasma Cell 1Glioma 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 8pembrolizumab 6Pemetrexed 6Radiotherapy 5Magnetic Resonance Spectroscopy 5Specimen Handling 4Radiation 4Nivolumab 4Bevacizumab 4Platinum 3Paclitaxel 3Mastectomy, Segmental 3Cisplatin 3Biopsy 3fludarabine phosphate 2durvalumab 2capmatinib 2aldesleukin 2Taxes 2Radiotherapy, Conformal 2Radiosurgery 2Ipilimumab 2Interleukin-2 2Immunoglobulin G 2Disulfides 2Cyclophosphamide 2CTLA-4 Antigen 2Anterior Temporal Lobectomy 21,2-diaminocyclohexaneplatinum II citrate 2veliparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma of Lung × Capsules × 1 year × Clear all
NCT04105270 2025-09-11

RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

Masonic Cancer Center, University of Minnesota

Phase 2 Recruiting
82 enrolled
Thoracic

Adenocarcinoma of Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡